Importantly, while this AML subset (herein referred to as AMLDNMT3A/FLT3/NPM1) seems to have unique characteristics at the mRNA, miRNA, and epigenetic levels [1], its clinical features are not known. This evidence concerns the gene FLT3 and acute myeloid leukemia.